OncoMatch/Clinical Trials/NCT04686682
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Is NCT04686682 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including JAB-8263 and JAB-8263 for nsclc.
Treatment: JAB-8263 · JAB-8263 — This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study. These two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Prostate Cancer
Ovarian Cancer
Acute Myeloid Leukemia
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
sufficient baseline organ function
Kidney function
sufficient baseline organ function
Liver function
sufficient baseline organ function
Patients who have sufficient baseline organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify